Poetic.Injustice
Member
BRENT SAUNDERS, the chief executive of Allergan, one of the largest pharmaceutical firms in the world, is concerned that in an era of increasing political polarization, Americans will become fed up and embrace the single-payer health care plan set to be unveiled Wednesday by Sen. Bernie Sanders, I-Vt.
He shared his candid thoughts last weekend at the Wells Fargo Healthcare Conference in Boston, a gathering for investors and major pharmaceutical and biotech firms.
Americans have lost trust in drug companies, Saunders said, noting the industry consistently ranks lower than oil and tobacco companies in public trust surveys.
I think weve got to do things to bring that trust back, the executive added, because ultimately, someones going to be in the White House. Somebodys going to be in Congress. Someones going to be somewhere and going to have to say, Enoughs enough. Lets just change the whole system. Lets go to one payer. Lets do something.'
While single payer has been discarded as a fringe, far-left idea over recent generations, the policy proposal has gained new traction in the wake of the 2016 presidential election. Many in the Democratic Party are drifting to the ideas of Sanders and other progressives who have long advocated for expanding coverage by providing Medicare to all Americans.
But if Saunders is concerned that the public may get fed up with the current system, it may have something to do with how Allergan itself has acted in recent weeks. The CEO has been under fire for taking the unprecedented step of transferring the patent of one of Allergans blockbuster drugs, the eye medication Restasis, to a sovereign Native American tribe as part of a bid to maintain monopoly control of the drug and its revenue.
The highly unusual legal strategy is designed to keep generic drug firms from challenging the Restasis patent, thus lowering the cost to consumers, while keeping Allergan in effective control of the revenue through its deal with the Saint Regis Mohawk Tribe. The Restasis patent was approved 15 years ago and was set to expire in 2014, but the Allergan deal is part of an attempt to renew the patent and extend the companys control of the drug through 2024.
https://theintercept.com/2017/09/13...and-embrace-bernie-sanders-single-payer-plan/